Angiotensin-Converting Enzyme Inhibitors
- 1 November 1988
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 15 (5) , 295-318
- https://doi.org/10.2165/00003088-198815050-00003
Abstract
The inter-relationship between the pharmacokinetic and pharmacodynamic behaviour of ACE inhibitors is reviewed. First, some of the methods which have been used to assess the pharmacodynamics of ACE inhibitors in humans are presented. They include humoral assays (e.g. ACE activity in plasma, renin activity, etc.), haemodynamic changes (blood pressure, total peripheral resistance, etc.) and agonist challenges (angiotensin I infusions). Subsequently a pharmacokinetic-dynamic model is described, based on biochemical processes obtained after ACE inhibition, which seems to be useful for the interpretation of the complex processes. The various correlations between plasma drug concentration on the one hand and plasma ACE activity, angiotensin II concentration in plasma or blood pressure on the other, are discussed on the basis of this model. From the model obtained it becomes obvious that under many circumstances the release of the inhibitor from ACE binding is the step which in fact determines the pharmacodynamically relevant elimination rate of the drug at low concentrations, whereas at high concentrations the elimination of the drug is mainly dependent on kidney (and/or liver) elimination rate. The dynamic-kinetic correlations are then presented for some ACE inhibitors in various disease states: arterial hypertension, heart failure, old age, renal failure, liver disease. In a final section the kinetic and dynamic relevance of interactions of ACE inhibitors with food and other drugs is described (e.g. prostaglandin inhibitors, diuretics, digoxin and cimetidine). Despite the great body of literature which deals with the kinetic and/or dynamic properties of ACE inhibitors, precise knowledge of the relationship between their kinetic and dynamic behaviour is rather limited and there is a clear need for further studies to elucidate this complex topic, thereby improving therapeutic possibilities with these useful new compounds.Keywords
This publication has 83 references indexed in Scilit:
- The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril.British Journal of Clinical Pharmacology, 1989
- Inhibition of renal clearance of furosemide by pentopril, an angiotensin—converting enzyme inhibitorClinical Pharmacology & Therapeutics, 1987
- The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure.British Journal of Clinical Pharmacology, 1987
- The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: Comparison with patients with normal renal functionEuropean Journal of Clinical Pharmacology, 1987
- Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin.British Journal of Clinical Pharmacology, 1986
- Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study.1986
- Time Course and Effect of Sodium Intake on Vascular and Hormonal Responses to Enalapril (MK 421) in Normal SubjectsJournal of Cardiovascular Pharmacology, 1983
- Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failureAmerican Heart Journal, 1982
- Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure.Hypertension, 1981
- Radioimmunoassay of angiotensin II in rat plasmaCellular and Molecular Life Sciences, 1973